SequelSEC

Pyxis Oncology, Inc. PYXS

Pharmaceutical Preparations · CIK 0001782223 · Fiscal year ends 1231

Revenue
$13.86M
Fiscal year ended 2025-12-31
Operating income
-$84.42M
Fiscal year ended 2025-12-31
Free cash flow
-$63.51M
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$64.40MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$1.02Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue4.6×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue0.1%9th
Gross margin82.8%71th
SBC / revenue85.2%67th
FCF margin-458.3%34th
Revenue YoY growth-14.2%34th
R&D / revenue531.8%66th
Net margin-574.5%37th
Operating margin-609.2%39th
Current ratio3.41x47th

Pyxis Oncology, Inc. (PYXS) reported revenue of $13.86M and net income of -$79.62M for the fiscal year ended 2025-12-31. This page shows 2 annual periods of income statement, balance sheet and cash flow figures normalized from Pyxis Oncology, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Pyxis Oncology, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Revenue$13.86M$16.15M
Cost of revenue$2.39M$475.00K
Gross profit$11.47M$15.67M
Operating income-$84.42M-$89.46M
Net income-$79.62M-$77.33M
Research & development$73.70M$58.75M
Weighted-average diluted sharesshares 62.14Mshares 58.45M
Pretax income-$78.24M-$79.50M
Income tax expense$1.39M-$2.16M
Diluted EPS$-1.28$-1.32
Selling, general & administrativeUnavailableUnavailable
General & administrative$22.19M$25.42M
Selling & marketingUnavailableUnavailable

Balance

Pyxis Oncology, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Cash & equivalents$15.42M$19.47M
Total assets$91.52M$157.18M
Current assets$72.10M$132.44M
Total liabilities$38.11M$36.43M
Current liabilities$21.13M$17.68M
Total equity incl. NCI$53.41M$120.75M
Temporary (mezzanine) equityUnavailableUnavailable
InventoryUnavailableUnavailable
Accounts receivableUnavailableUnavailable
GoodwillUnavailableUnavailable
Long-term debtUnavailableUnavailable
Accounts payable$10.88M$4.86M

Cash flow

Pyxis Oncology, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Operating cash flow-$63.50M-$57.67M
Capital expenditures$9.00K$237.00K
Investing cash flow$58.86M$8.16M
Financing cash flow$594.00K$59.33M
Net change in cash-$4.05M$9.81M
Stock-based compensation$11.80M$12.94M
Common dividends paidUnavailableUnavailable
Common share repurchasesUnavailableUnavailable
Depreciation & amortization$4.51M$2.98M

Derived

Pyxis Oncology, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Free cash flow-$63.51M-$57.91M
Gross margin82.8%97.1%
Operating margin-609.2%-554.1%
FCF margin-458.3%-358.7%
SBC / revenue85.2%80.2%
Current ratio3.41x7.49x
Revenue YoY growth-14.2%Unavailable
Net margin-574.5%-478.9%
R&D / revenue531.8%363.8%
CapEx / revenue0.1%1.5%
Long-term debt / equityUnavailableUnavailable
Effective tax rateUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PYXS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-23View SEC filing
10-Q · Filed 2025-11-03View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.